Financial Instruments and Risk Management (Rollforward of Contingent Consideration) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($)
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	$ 215.1
Acquisition	345.0
Payments	10.9
Reclassifications	0.0
Accretion expense	15.9
Fair value loss	4.8
Balance at end of period	569.9
Biocon Biologics
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	15.8
Balance at end of period	30.0
Other Current Liabilities [Member]
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	76.1
Acquisition	0.0
Payments	10.9
Reclassifications	40.0
Accretion expense	0.0
Fair value loss	0.0
Balance at end of period	105.2
Other long-term obligations
Schedule of Activity in Contingent Consideration [Roll Forward]
Balance at beginning of period	139.0
Acquisition	345.0
Payments	0.0
Reclassifications	(40.0)
Accretion expense	15.9
Fair value loss	4.8
Balance at end of period	$ 464.7